首页 > 市场调查报告书 > 医疗设备

心血管设备

市场调查报告书

商品编码

1510442

心臟帮浦设备市场规模 - 按类型（植入式、体外）、设备（心室辅助设备、全人工心臟、主动脉内球囊帮浦、体外膜氧合）、治疗、最终用途和预测，2024 - 2032 年

Heart Pump Device Market Size - By Type (Implanted, Extracorporeal), Device (Ventricular Assist Devices, Total Artificial Hearts, Intra-Aortic Balloon Pumps, Extracorporeal Membrane Oxygenation), Therapy, End-use & Forecast, 2024 - 2032

出版日期: 2024年04月01日 | 出版商:

Global Market Insights Inc. | 英文 160 Pages | 商品交期: 2-3个工作天内

价格

简介目录

在全球心血管疾病盛行率上升的推动下，2024 年至 2032 年间，心泵设备市场规模的复合年增长率将达到 17.4%。根据英国心臟基金会的统计，估计有 2 亿人患有心血管疾病。近年来，心臟衰竭、冠状动脉疾病和心肌病变等疾病已成为心臟泵设备需求不断增长的主要原因。此外，人口老化的加剧以及不健康生活方式和肥胖的增加正在增加心血管疾病的风险，有利于产品需求。

与心臟帮浦装置相关的微创手术，包括更短的恢復时间、更低的併发症风险和更好的患者治疗结果，有助于提高医疗保健提供者和患者的接受度。主要市场参与者的策略性倡议，包括产品创新、策略合作和扩大产品组合的收购，也刺激了市场成长。

整个产业分为类型、设备、治疗、最终用途和地区。

根据治疗，预计到2032 年，从过渡到恢復(BTR) 治疗领域的心臟泵设备市场复合年增长率将达到16%，这得益于其为等待心臟移植或康復的严重心臟衰竭患者提供的临时循环支援。对于不适合紧急心臟移植并需要额外支持以帮助心臟从急性心臟病发作中恢復的患者来说，这种疗法是救星。用于心肺復苏术的心臟帮浦装置，例如心室辅助装置 (VAD)，也提供机械循环支持，以改善心臟功能，让患者在等待进一步治疗时稳定并恢復体力。

由于为终末期心臟衰竭患者提供全面解决方案的需求不断增长，预计 2024 年至 2032 年，整个人工心臟 (TAH) 领域的心臟泵设备市场将产生高收入，复合年增长率为 21.7%。全心臟被设计为移植的桥樑或作为不适合移植的患者的永久解决方案。设备技术的快速进步，包括提高生物相容性、耐用性、尺寸更小以改善患者治疗效果以及扩大相关患者群体，有利于该细分市场的成长。

2024年至2032年，亚太地区心泵设备产业规模将以18.8%的复合年增长率快速扩张。快速的城市化和工业化增加了与生活方式相关的风险因素，从而提高了该地区心血管疾病的发生率。中国、印度和日本等国家医疗保健基础设施的进步、收入的增加和医疗保健支出的增加，透过改善患者获得先进心臟治疗（包括心泵设备）的机会来推动市场成长。

产业生态系统分析
产业影响力
- 成长动力
  - 心臟衰竭和心血管疾病的数量增加
  - 技术进步
  - 提高对心臟衰竭治疗的认识
  - 研发支出不断成长
- 产业陷阱与挑战
  - 严格的监管场景
  - 设备和流程成本高
成长潜力分析
波特的分析
PESTEL分析
未来市场趋势
报销场景
监管环境
技术景观
缺口分析

第 4 章：竞争格局

介绍
公司矩阵分析
公司市占率分析
竞争定位矩阵
战略仪表板

第 5 章：市场估计与预测：按类型，2021 - 2032

主要趋势
植入式心臟帮浦装置
体外心臟帮浦装置

第 6 章：市场估计与预测：按设备分类，2021 - 2032 年

主要趋势
心室辅助装置 (VAD)
- 左心室辅助装置 (LVAD)
- 右心室辅助装置 (RVAD)
- 双心室辅助装置 (BiVAD)
- 经皮心室辅助装置 (PVAD)
全人工心臟 (TAH)
主动脉内球囊反搏帮浦 (IABP)
体外膜氧合（ECMO）

第 7 章：市场估计与预测：按治疗方式，2021 - 2032 年

主要趋势
目的地治疗
候选过渡 (BTC) 疗法
移植桥 (BTT) 疗法
復健过渡 (BTR) 疗法
其他疗法

第 8 章：市场估计与预测：按最终用途，2021 - 2032 年

主要趋势
医院
心臟中心
门诊手术中心
其他最终用户

第 9 章：市场估计与预测：按地区，2021 - 2032

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 义大利
- 西班牙
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地区
中东和非洲
- 沙乌地阿拉伯
- 南非
- 阿联酋
- 中东和非洲其他地区

第 10 章：公司简介

Abbott Laboratories
ABIOMED
Berlin Heart
BiVACOR Inc.
CARMAT
CorWave SA
Evaheart, Inc.
Fresenius SE & Co. KGaA
Getinge AB
Jarvik Heart
Leviticus Cardio
LivaNova PLC
Medtronic plc
SynCardia Systems, LLC
Teleflex Incorporated

简介目录

Product Code: 8787

Heart pump device market size will register 17.4% CAGR between 2024 and 2032, driven by rising prevalence of cardiovascular diseases worldwide. As per British Heart Foundation, an estimated 200 million people suffer from cardiovascular disorders. Of late, diseases, such as heart failure, coronary artery disease, and cardiomyopathy have become the major reasons for the growing demand for heart pump devices. Moreover, the growing aging population along with the rising unhealthy lifestyles and obesity are increasing the risk of cardiovascular diseases, favoring the product demand.

Minimally invasive procedures associated with heart pumping devices, including shorter recovery times, lower risk of complications, and better patient outcomes are contributing to their increased acceptance among healthcare providers and patients. Strategic initiatives by key market players including product innovations, strategic collaborations, and acquisitions for expanding product portfolios is also stimulating the market growth.

The overall industry is segmented into type, device, therapy, end-use and region.

Based on therapy, the heart pump device market from the bridge to recovery (BTR) therapy segment is anticipated to witness 16% CAGR through 2032, backed by its temporary circulatory support to patients with severe heart failure while awaiting heart transplantation or recovery. This therapy is a lifesaver for patients who are not eligible for an urgent heart transplant and need extra support to help their heart recover from an acute heart attack. Heart pumping devices used in cardiopulmonary resuscitation, such as ventricular assist devices (VADs) also provide mechanical circulatory support to improve heart function and allow patients to stabilize and regain strength while awaiting further treatment.

Heart pump device market from the total artificial hearts (TAH) segment is estimated to generate high revenue at 21.7% CAGR from 2024 to 2032, favored by the rising need for offering a comprehensive solution for patients with end-stage heart failure. Total hearts are designed as a bridge to transplantation or as a permanent solution for patients who are not transplant candidates. Rapid advancements in device technology, including improved biocompatibility, durability, smaller for better patient outcomes and expanding relevant patient populations is favoring the segment growth.

Asia Pacific heart pump device industry size will witness rapid expansion at 18.8% CAGR between 2024-2032. The rapid urbanization and industrialization are contributing to lifestyle-related risk factors, elevating the incidence of CVDs in the region. Advancements in healthcare infrastructure, rising incomes, and healthcare spending in countries, such as China, India, and Japan are driving market growth by improving patient access to advanced cardiac treatments, including heart pump devices.

Chapter 1 Methodology & Scope

1.1 Market scope & definition
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360-degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increase in number of heart failures and cardiovascular diseases
  - 3.2.1.2 Technological advancements
  - 3.2.1.3 Rise in awareness regarding heart failure treatment
  - 3.2.1.4 Growing R&D expenditure
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Stringent regulatory scenario
  - 3.2.2.2 High cost of device and procedures
3.3 Growth potential analysis
3.4 Porter's analysis
3.5 PESTEL analysis
3.6 Future market trends
3.7 Reimbursement scenario
3.8 Regulatory landscape
3.9 Technological landscape
3.10 GAP analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Implanted heart pump devices
5.3 Extracorporeal heart pump devices

Chapter 6 Market Estimates and Forecast, By Device, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Ventricular assist devices (VADs)
- 6.2.1 Left ventricular assist devices (LVAD)
- 6.2.2 Right ventricular assist devices (RVAD)
- 6.2.3 Bi-ventricular assist devices (BiVAD)
- 6.2.4 Percutaneous ventricular assist devices (PVAD)
6.3 Total artificial hearts (TAHs)
6.4 Intra-aortic balloon pumps (IABPs)
6.5 Extracorporeal membrane oxygenation (ECMO)

Chapter 7 Market Estimates and Forecast, By Therapy, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Destination therapy
7.3 Bridge-to-candidacy (BTC) therapy
7.4 Bridge-to-transplant (BTT) therapy
7.5 Bridge-to-recovery (BTR) therapy
7.6 Other therapies

Chapter 8 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospitals
8.3 Cardiac centers
8.4 Ambulatory surgical centers
8.5 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Italy
- 9.3.5 Spain
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 Saudi Arabia
- 9.6.2 South Africa
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa